Fakhari Solmaz, Bavil Fariba Mirzaei, Bilehjani Eissa, Abolhasani Sona, Mirinazhad Moussa, Naghipour Bahman
Department of Anesthesiology.
Department of Physiology.
Res Rep Urol. 2017 Jan 19;9:5-13. doi: 10.2147/RRU.S126134. eCollection 2017.
Acute renal dysfunction is a common complication of cardiac surgery. Furosemide is used in prevention, or treatment, of acute renal dysfunction. This study was conducted to evaluate the protective effects of intra- and early postoperative furosemide infusion on preventing acute renal dysfunction in elective adult cardiac surgery.
Eighty-one patients, candidates of elective cardiac surgery, were enrolled in this study in either the furosemide (n=41) or placebo (n=40) group. Furosemide (2 mg/h) or 0.9% saline was administered and continued up to 12 hours postoperatively. We measured serum creatinine (Scr) at preoperative and on the second and fifth postoperative days. Then calculated estimated glomerular filtration rate (eGFR) at these times. An increase in Scr of >0.5 mg/dL and/or >25%-50%, compared to preoperative values, was considered as acute kidney injury (AKI). In contrast, an increase in Scr by >50% and/or the need for hemodialysis was regarded as acute renal failure (ARF). At the end we compared the AKI or ARF incidence between the two groups.
On the second and fifth postoperative days, Scr was lower, and the eGFR was higher in the furosemide group. AKI incidence was similar in the two groups (11 vs 12 cases; -value 0.622); however, ARF rate was lower in furosemide group (1 vs 6 cases; -value 0.044). During the study period, Scr was more stable in the furosemide group, however in the placebo group, Scr initially increased and then decreased to its preoperative value after a few days.
This study showed that intra- and early postoperative furosemide infusion has a renal protective effect in adult cardiac surgery with cardiopulmonary bypass. Although this protective effect cannot be discovered in mild renal dysfunctions, it apparently reduces the rate of the more severe renal dysfunctions. A more multidisciplinary strategy may be needed in reducing the milder renal damage.
急性肾功能障碍是心脏手术常见的并发症。速尿用于预防或治疗急性肾功能障碍。本研究旨在评估术中及术后早期输注速尿对择期成人心脏手术中预防急性肾功能障碍的保护作用。
81例择期心脏手术患者纳入本研究,分为速尿组(n = 41)和安慰剂组(n = 40)。给予速尿(2mg/h)或0.9%生理盐水,并持续至术后12小时。我们在术前、术后第二天和第五天测量血清肌酐(Scr)。然后在这些时间计算估计肾小球滤过率(eGFR)。与术前值相比,Scr升高>0.5mg/dL和/或>25%-50%被视为急性肾损伤(AKI)。相反,Scr升高>50%和/或需要血液透析被视为急性肾衰竭(ARF)。最后,我们比较了两组之间AKI或ARF的发生率。
术后第二天和第五天,速尿组Scr较低,eGFR较高。两组AKI发生率相似(11例对12例;P值0.622);然而,速尿组ARF发生率较低(1例对6例;P值0.044)。在研究期间,速尿组Scr更稳定,而在安慰剂组中,Scr最初升高,几天后降至术前值。
本研究表明,术中及术后早期输注速尿对体外循环下的成人心脏手术具有肾脏保护作用。虽然这种保护作用在轻度肾功能障碍中未被发现,但它显然降低了更严重肾功能障碍的发生率。在减少较轻的肾脏损害方面可能需要更具多学科性的策略。